Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Open-label Phase II Study of Induction Standard of Care Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

NCT04920708 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT04920708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04920708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Open-label Phase II Study of Induction Standard of Care Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 28, 2022
Completion date
June 30, 2027
Enrollment
57 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, er+ breast cancer, metastatic breast cancer